Rehmannia glutinosa suppresses inflammatory responses elicited by advanced glycation end products

Inflammation

Volumn 35, Issue 4, 2012, Pages 1232-1241

  Baek, Gui Hyun ^a   Jang, Yong Suk ^a   Jeong, Seung Il ^b   Cha, Jaeho ^c   Joo, Myungsoo ^c   Shin, Sang Woo ^c   Ha, Ki Tae ^c   Jeong, Han Sol ^c  

^a Chonbuk National University   (South Korea)

^b Jeonju Bio Materials Institute   (South Korea)

^c Pusan National University   (South Korea)

Author keywords

Advanced glycation end products; NF B; Pro inflammation; Rehmannia glutinosa; THP 1

Indexed keywords

1,1 DIPHENYL 2 PICRYLHYDRAZYL; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BUTYLCRESOL; CYCLOOXYGENASE 2; DICHLORODIHYDROFLUORESCEIN DIACETATE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; REHMANNIA GLUTINOSA EXTRACT; TUMOR NECROSIS FACTOR ALPHA; WATER;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFICACY; FREE RADICAL SCAVENGING ACTIVITY; FREEZE DRYING; GENE ACTIVATION; GENE REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; NONHUMAN; REHMANNIA; REHMANNIA GLUTINOSA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHIZOME; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CELL LINE; CHEMOKINE CCL2; CHEMOKINE CXCL10; CYCLOOXYGENASE 2; DIABETES COMPLICATIONS; DIABETES MELLITUS; DOWN-REGULATION; FREE RADICAL SCAVENGERS; GLYCOSYLATION END PRODUCTS, ADVANCED; INFLAMMATION; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; PLANT EXTRACTS; REACTIVE OXYGEN SPECIES; RECEPTORS, IMMUNOLOGIC; REHMANNIA; RHIZOME; TUMOR NECROSIS FACTOR-ALPHA;

REHMANNIA GLUTINOSA;

EID: 84866732340     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-012-9433-x     Document Type: Article

References (57)

1. Ahmed, N. 2005. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Research and Clinical Practice 67: 3-21.
2. Bierhaus, A., M.A. Hofmann, R. Ziegler, and P.P. Nawroth. 1998. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovascular Research 37: 586-600.
3. Singh, R., A. Barden, T. Mori, and L. Beilin. 2001. Advanced glycation end-products: A review. Diabetologia 44: 129-146.
4. Turk, Z., S. Ljubic, N. Turk, and B. Benko. 2001. Detection of autoantibodies against advanced glycation endproducts and AGEimmune complexes in serum of patients with diabetes mellitus. Clinica chimica acta; international journal of clinical chemistry 303: 105-115.
5. Yamamoto, Y., I. Kato, T. Doi, H. Yonekura, S. Ohashi, M. Takeuchi, et al. 2001. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. The Journal of Clinical Investigation 108: 261-268.
6. Harja, E., D.X. Bu, B.I. Hudson, J.S. Chang, X. Shen, K. Hallam, et al. 2008. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/-mice. The Journal of Clinical Investigation 118: 183-194.
7. Forbes, J.M., L.T. Yee, V. Thallas, M. Lassila, R. Candido, K.A. Jandeleit-Dahm, et al. 2004. Advanced glycation end product interventions reduce diabetes-Accelerated atherosclerosis. Diabetes 53: 1813-1823.
8. Wada, R., and S. Yagihashi. 2005. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Annals of the New York Academy of Sciences 1043: 598-604.
9. Peyroux, J., and M. Sternberg. 2006. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathologie-Biologie 54: 405-419.
10. Fosmark, D.S., P.A. Torjesen, B.K. Kilhovd, T.J. Berg, L. Sandvik, K.F. Hanssen, et al. 2006. Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism, Clinical and Experimental 55: 232-236.
11. Huebschmann, A.G., J.G. Regensteiner, H. Vlassara, and J.E. Reusch. 2006. Diabetes and advanced glycoxidation end products. Diabetes Care 29: 1420-1432.
12. Desai, K., and L. Wu. 2007. Methylglyoxal and advanced glycation endproducts: new therapeutic horizons? Recent Patents on Cardiovascular Drug Discovery 2: 89-99.
13. Edelstein, D., and M. Brownlee. 1992. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 41: 26-29.
14. Nakamura, S., Z. Makita, S. Ishikawa, K. Yasumura, W. Fujii, K. Yanagisawa, et al. 1997. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46: 895-899.
15. Doggrell, S.A. 2001. ALT-711 decreases cardiovascular stiffness and has potential in diabetes, hypertension and heart failure. Expert Opinion on Investigational Drugs 10: 981-983.
16. Oturai, P.S., M. Christensen, B. Rolin, K.E. Pedersen, S.B. Mortensen, and E. Boel. 2000. Effects of advanced glycation end-product inhibition and cross-link breakage in diabetic rats. Metabolism, Clinical and Experimental 49: 996-1000.
17. Stitt, A., T.A. Gardiner, N.L. Alderson, P. Canning, N. Frizzell, N. Duffy, et al. 2002. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51: 2826-2832.
18. Figarola, J.L., S. Scott, S. Loera, C. Tessler, P. Chu, L. Weiss, et al. 2003. LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocindiabetic rats. Diabetologia 46: 1140-1152.
19. Huang, W.J., H.S. Niu, M.H. Lin, J.T. Cheng, and F.L. Hsu. 2010. Antihyperglycemic effect of catalpol in streptozotocin-induced diabetic rats. Journal of Natural Products 73: 1170-1172.
20. Kubo, M., T. Asano, H. Shiomoto, and H. Matsuda. 1994. Studies on rehmanniae radix. I. Effect of 50% ethanolic extract from steamed and dried rehmanniae radix on hemorheology in arthritic and thrombosic rats. Biological and Pharmaceutical Bulletin 17: 1282-1286.
21. Kiho, T., T. Watanabe, K. Nagai, and S. Ukai. 1992. Hypoglycemic activity of polysaccharide fraction from rhizome of Rehmannia glutinosa Libosch. f. hueichingensis Hsiao and the effect on carbohydrate metabolism in normal mouse liver. Yakugaku zasshi: Journal of the Pharmaceutical Society of Japan 112: 393-400.
22. Yokozawa, T., H.Y. Kim, and N. Yamabe. 2004. Amelioration of diabetic nephropathy by dried rehmanniae radix (Di Huang) extract. The American Journal of Chinese Medicine 32: 829-839.
23. Kang, D.G., E.J. Sohn, M.K. Moon, Y.M. Lee, and H.S. Lee. 2005. Rehmannia glutinose ameliorates renal function in the ischemia/ reperfusion-induced acute renal failure rats. Biological and Pharmaceutical Bulletin 28: 1662-1667.
24. Kim, H.M., C.S. An, K.Y. Jung, Y.K. Choo, J.K. Park, and S.Y. Nam. 1999. Rehmannia glutinosa inhibits tumour necrosis factor-Alpha and interleukin-1 secretion from mouse astrocytes. Pharmacological research: The official journal of the Italian Pharmacological Society 40: 171-176.
25. Ashoor, S.H., and J.B. Zent. 1984. Maillard browning of common amino-Acids and sugars. Journal of Food Science 49: 1206-1207.
26. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. Journal of Immunological Methods 65: 55-63.
27. Brandwilliams, W., M.E. Cuvelier, and C. Berset. 1995. Use of a free-radical method to evaluate antioxidant activity. Food Sci Technol-Lebensm-Wiss Technol 28: 25-30.
28. Ramasamy, R., S.J. Vannucci, S.S. Yan, K. Herold, S.F. Yan, and A.M. Schmidt. 2005. Advanced glycation end products and RAGE: A common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15: 16R-28R.
29. Baeuerle, P.A., and D. Baltimore. 1996. NF-kappa B: Ten years after. Cell 87: 13-20.
30. Barnes, P.J., and M. Karin. 1997. Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. The New England Journal of Medicine 336: 1066-1071.
31. May, M.J., and S. Ghosh. 1997. Rel/NF-kappa B and I kappa B proteins: An overview. Seminars in Cancer Biology 8: 63-73.
32. Collins, T. 1993. Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. Laboratory investigation; a journal of technical methods and pathology 68: 499-508.
33. Read, M.A., M.Z. Whitley, A.J. Williams, and T. Collins. 1994. NF-kappa B and I kappa B alpha: An inducible regulatory system in endothelial activation. The Journal of Experimental Medicine 179: 503-512.
34. Verma, I.M., J.K. Stevenson, E.M. Schwarz, D. Van Antwerp, and S. Miyamoto. 1995. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes & Development 9: 2723-2735.
35. Pouliot, M., J. Baillargeon, J.C. Lee, L.G. Cleland, and M.J. James. 1997. Inhibition of prostaglandin endoperoxide synthase-2 expression in stimulated human monocytes by inhibitors of p38 mitogen-Activated protein kinase. Journal of Immunology 158: 4930-4937.
36. Zhang, G., and S. Ghosh. 2001. Toll-like receptor-mediated NFkappaB activation: A phylogenetically conserved paradigm in innate immunity. The Journal of Clinical Investigation 107: 13-19.
37. Lander, H.M., J.S. Ogiste, R.A. Moss, D. Stern, and A.M. Schmidt. 1995. Advanced glycation endproducts (ages) induce activation of nuclear factor-kappaB (NF-kB) by a signaling mechanism involving p21(ras) and map kinase via the receptor for ages (rage). Circulation 92: 532-532.
38. Schmidt, A.M., O. Hori, R. Cao, S.D. Yan, J. Brett, J.L. Wautier, et al. 1996. RAGE-A novel cellular receptor for advanced glycation end products. Diabetes 45: S77-S80.
39. Sousa, M.M., S. Du Yan, D. Stern, and M.J. Saraiva. 2000. Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Laboratory Investigation 80: 1101-1110.
40. Vlassara,H., andM.R. Palace. 2002.Diabetes and advanced glycation endproducts. Journal of Internal Medicine 251: 87-101.
41. Brownlee, M. 2005. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 54: 1615-1625.
42. Yan, S.D., A.M. Schmidt, G.M. Anderson, J.H. Zhang, J. Brett, Y.S. Zou, et al. 1994. Enhanced cellular oxidant stress by the interaction of advanced glycation end-products with their receptors bindingproteins. Journal of Biological Chemistry 269: 9889-9897.
43. Lander, H.M., J.M. Tauras, J.S. Ogiste, O. Hori, R.A. Moss, and A.M. Schmidt. 1997. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogenactivated protein kinase pathway regulated by oxidant stress. Journal of Biological Chemistry 272: 17810-17814.
44. Stern, D., S.D. Yan, S.F. Yan, and A.M. Schmidt. 2002. Receptor for advanced glycation endproducts: A multiligand receptor magnifying cell stress in diverse pathologic settings. Advanced Drug Delivery Reviews 54: 1615-1625.
45. Yamagishi, S.I., K. Nakamura, T. Matsui, S. Ueda, K. Fukami, and S. Okuda. 2008. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: A novel therapeutic strategy for diabetic vascular complications. Expert Opinion on Investigational Drugs 17: 983-996.
46. Jiang, Y., D.I. Beller, G. Frendl, and D.T. Graves. 1992. Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. Journal of Immunology 148: 2423-2428.
47. Wakabayashi, Y., Y. Usui, Y. Okunuki, T. Kezuka, M. Takeuchi, H. Goto, et al. 2010. Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy. Retina 30: 339-344.
48. Miura, T., M. Kako, E. Ishihara, M. Usami, H. Yano, K. Tanigawa, et al. 1997. Antidiabetic effect of seishin-kanro-To in KK-Ay mice. Planta Medica 63: 320-322.
49. Meng, Q.Y., X.F. Lv, and X.D. Jin. 2008. [Effect of Rehmannia glutinosa Libosch water extraction on gene expression of proinsulin in type 2 diabetes mellitus rats]. Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials 31: 397-399.
50. Waisundara, V.Y., M. Huang, A. Hsu, D. Huang, and B.K. Tan. 2008. Characterization of the anti-diabetic and antioxidant effects of Rehmannia glutinosa in streptozotocin-induced diabetic Wistar rats. The American Journal of Chinese Medicine 36: 1083-1104.
51. Lee, H.S., S.T. Kim, and D.K. Cho. 1993. Effects of rehmanniae radix water extract on renal function and renin secretion rate in unanesthetized rabbits. The American Journal of Chinese Medicine 21: 179-186.
52. Li, S.L., J.Z. Song, C.F. Qiao, Y. Zhou, K. Qian, K.H. Lee, et al. 2010. A novel strategy to rapidly explore potential chemical markers for the discrimination between raw and processed radix rehmanniae by UHPLC-TOFMS with multivariate statistical analysis. Journal of Pharmaceutical and Biomedical Analysis 51: 812-823.
53. Huang, W.J., F.S. Niu, M.H. Lin, J.T. Cheng, and F.L. Hsu. 2010. Antihyperglycemic effect of catalpol in streptozotocin-induced diabetic rats. Journal of Natural Products 73: 1170-1172.
54. Wang, C.F., D.Q. Li, H.Y. Xue, and B. Hu. 2010. Oral supplementation of catalpol ameliorates diabetic encephalopathy in rats. Brain Research 1307: 158-165.
55. Shieh, J.P., K.C. Cheng, H.H. Chung, Y.F. Kerh, C.H. Yeh, and J.T. Cheng. 2011. Plasma glucose lowering mechanisms of catalpol, an active principle from roots of Rehmannia glutinosa, in streptozotocininduced diabetic rats. Journal of Agricultural and Food Chemistry 59: 3747-3753.
56. Tian, Y.Y., L.J. An, L. Jiang, Y.L. Duan, J. Chen, and B. Jiang. 2006. Catalpol protects dopaminergic neurons from LPS-induced neurotoxicity in mesencephalic neuron-glia cultures. Life Sciences 80: 193-199.
57. Bi, J., B. Jiang, J.H. Liu, C. Lei, X.L. Zhang, and L.J. An. 2008. Protective effects of catalpol against H2O2-induced oxidative stress in astrocytes primary cultures. Neuroscience Letters 442: 224-227.